EA201200999A1 - Способы лечения рака молочной железы - Google Patents

Способы лечения рака молочной железы

Info

Publication number
EA201200999A1
EA201200999A1 EA201200999A EA201200999A EA201200999A1 EA 201200999 A1 EA201200999 A1 EA 201200999A1 EA 201200999 A EA201200999 A EA 201200999A EA 201200999 A EA201200999 A EA 201200999A EA 201200999 A1 EA201200999 A1 EA 201200999A1
Authority
EA
Eurasian Patent Office
Prior art keywords
breast cancer
methods
treatment breast
treatment
progastrin
Prior art date
Application number
EA201200999A
Other languages
English (en)
Other versions
EA025329B1 (ru
Inventor
Жан-Франсуа Флош
Лейла Уу
Франсуа Келлер
Доминик Жубер
Фредерик Олланд
Original Assignee
Биориалите
Инститю Насьональ Де-Ла-Санте Эт Де-Ла-Решерш Медикаль (Инсерм)
Сантр Насьональ Де-Ла Решерш Сьентифик (Снрс)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биориалите, Инститю Насьональ Де-Ла-Санте Эт Де-Ла-Решерш Медикаль (Инсерм), Сантр Насьональ Де-Ла Решерш Сьентифик (Снрс) filed Critical Биориалите
Publication of EA201200999A1 publication Critical patent/EA201200999A1/ru
Publication of EA025329B1 publication Critical patent/EA025329B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее описание относится к способам лечения и профилактики рака молочной железы или рецидива рака молочной железы с помощью композиций, содержащих антитела к прогастрину.
EA201200999A 2010-01-08 2011-01-07 Способы профилактики или предотвращения рецидивов или лечения рака молочной железы EA025329B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29361210P 2010-01-08 2010-01-08
PCT/EP2011/000048 WO2011083090A2 (en) 2010-01-08 2011-01-07 Methods for treating breast cancer

Publications (2)

Publication Number Publication Date
EA201200999A1 true EA201200999A1 (ru) 2013-02-28
EA025329B1 EA025329B1 (ru) 2016-12-30

Family

ID=43607948

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201200999A EA025329B1 (ru) 2010-01-08 2011-01-07 Способы профилактики или предотвращения рецидивов или лечения рака молочной железы
EA201200998A EA023722B1 (ru) 2010-01-08 2011-01-07 ПРИМЕНЕНИЕ АНТИТЕЛА К ЧЕЛОВЕЧЕСКОМУ ПРОГАСТРИНУ (hPG) ДЛЯ ЛЕЧЕНИЯ РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201200998A EA023722B1 (ru) 2010-01-08 2011-01-07 ПРИМЕНЕНИЕ АНТИТЕЛА К ЧЕЛОВЕЧЕСКОМУ ПРОГАСТРИНУ (hPG) ДЛЯ ЛЕЧЕНИЯ РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ

Country Status (15)

Country Link
US (2) US9487582B2 (ru)
EP (2) EP2542583B8 (ru)
JP (2) JP6134141B2 (ru)
KR (2) KR101468397B1 (ru)
CN (2) CN102933603B (ru)
AU (2) AU2011204653B2 (ru)
BR (2) BR112012016820A2 (ru)
CA (2) CA2786435C (ru)
EA (2) EA025329B1 (ru)
ES (2) ES2657245T3 (ru)
NZ (2) NZ601591A (ru)
PL (2) PL2542583T3 (ru)
SG (2) SG182331A1 (ru)
WO (2) WO2011083091A2 (ru)
ZA (2) ZA201205004B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
EP2598531B1 (en) * 2010-07-26 2020-12-30 Progastrine et Cancers S.à r.l. Methods and compositions for liver cancer therapy
CA2996205A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
ES2861587T3 (es) * 2015-12-31 2021-10-06 Progastrine Et Cancers S A R L Composiciones y métodos para detectar y tratar el cáncer de esófago
SG11201805141QA (en) * 2015-12-31 2018-07-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating gastric cancer
WO2017114972A1 (en) * 2015-12-31 2017-07-06 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
TN2018000197A1 (en) 2015-12-31 2019-10-04 Syncerus S A R L Compositions and methods for assessing the risk of cancer occurrence
CN110402143B (zh) * 2017-01-06 2022-11-22 雷莫内克斯生物制药有限公司 预防或治疗转移性卵巢癌、子宫内膜癌或乳腺癌的组合物
ES2926532T3 (es) 2017-03-30 2022-10-26 Progastrine Et Cancers S A R L Composiciones y métodos para tratar el cáncer de pulmón
JP7071994B2 (ja) 2017-03-30 2022-05-19 プロガストリン、エ、カンセル、エス、アー エル、エル 前立腺がんを治療するための組成物および方法
US11267881B2 (en) 2017-09-14 2022-03-08 Charles ROSSER Compositions and methods for treatment of diseases involving CXCL1 function
JP7104153B2 (ja) * 2017-12-05 2022-07-20 プロガストリン、エ、カンセル、エス、アー エル、エル 癌を治療するための抗プロガストリン抗体と免疫療法の併用療法
CA3085067A1 (en) 2017-12-08 2019-06-13 Ecs-Biotracker Sarl Radiolabeled progastrin in cancer diagnosis
WO2019145537A1 (en) 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
AU2019236091A1 (en) * 2018-03-13 2020-09-03 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
CN108864255B (zh) * 2018-06-21 2022-01-04 天津医科大学肿瘤医院 一种乳腺癌干细胞特异性结合多肽及其在制备治疗乳腺癌药物中的应用
CA3127943A1 (en) * 2019-01-28 2020-08-06 Charles J. Rosser Compositions and methods for treatment of diseases involving cxcl1 function

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
NZ511550A (en) * 1997-05-12 2005-03-24 Aphton Corp CCK-B/gastrin receptor inhibitors for the treatment of tumors
CA2400874A1 (en) 2000-02-25 2001-08-30 The Regents Of The University Of California Membrane estrogen receptor-directed therapy in breast cancer
FR2846426B1 (fr) 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2006032980A1 (en) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Monoclonal antibolies to progastrin
CN101460196A (zh) * 2006-05-22 2009-06-17 国立医学与健康研究所 在结肠癌治疗中的前胃泌素抑制剂
JPWO2008032876A1 (ja) 2006-09-15 2010-01-28 学校法人東海大学 Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法
US20100092476A1 (en) 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
CA2700673A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
WO2011045080A2 (en) * 2009-10-16 2011-04-21 Biorealites S.A.S. Monoclonal antibodies to progastrin and their uses

Also Published As

Publication number Publication date
CN102892784B (zh) 2016-06-22
US20110177062A1 (en) 2011-07-21
ES2657245T3 (es) 2018-03-02
US9487582B2 (en) 2016-11-08
JP5572718B2 (ja) 2014-08-13
US8900588B2 (en) 2014-12-02
WO2011083090A3 (en) 2011-10-06
ZA201205003B (en) 2013-09-25
PL2542584T3 (pl) 2018-04-30
BR112012016742A2 (pt) 2018-05-15
EA023722B1 (ru) 2016-07-29
EA201200998A1 (ru) 2013-02-28
KR101438362B1 (ko) 2014-09-05
KR20130028050A (ko) 2013-03-18
KR20120135401A (ko) 2012-12-13
EP2542583B8 (en) 2017-12-13
CA2786479C (en) 2016-03-15
AU2011204653B2 (en) 2014-04-10
CA2786479A1 (en) 2011-07-14
EA025329B1 (ru) 2016-12-30
WO2011083091A8 (en) 2012-08-09
BR112012016820A2 (pt) 2023-11-28
KR101468397B1 (ko) 2014-12-04
EP2542584B1 (en) 2017-10-25
EP2542584A2 (en) 2013-01-09
JP6134141B2 (ja) 2017-05-24
NZ601591A (en) 2015-01-30
AU2011204653A1 (en) 2012-07-26
AU2011204654B2 (en) 2014-04-10
AU2011204654A1 (en) 2012-07-26
NZ601588A (en) 2014-07-25
WO2011083091A2 (en) 2011-07-14
CN102933603A (zh) 2013-02-13
US20110171213A1 (en) 2011-07-14
PL2542583T3 (pl) 2018-04-30
JP2013516438A (ja) 2013-05-13
ZA201205004B (en) 2013-09-25
EP2542583B1 (en) 2017-10-25
SG182331A1 (en) 2012-08-30
WO2011083091A3 (en) 2011-09-09
JP2013516439A (ja) 2013-05-13
CA2786435C (en) 2017-01-17
WO2011083090A2 (en) 2011-07-14
ES2657246T3 (es) 2018-03-02
CN102933603B (zh) 2016-01-20
CN102892784A (zh) 2013-01-23
EP2542583A2 (en) 2013-01-09
EP2542584B8 (en) 2017-12-13
CA2786435A1 (en) 2011-07-14
SG182334A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201201000A1 (ru) Способы лечения колоректального рака
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
EA201400178A1 (ru) Лечение рака молочной железы
PH12017500864A1 (en) Anti-notch1 antibodies
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
MX2016002571A (es) Regulador de ph de transduccion.
MY173839A (en) Cd37-binding molecules and immunoconjugates thereof
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201291194A1 (ru) Индолы
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX348637B (es) Anticuerpos y composiciones anti-her3.
MX347020B (es) Anticuerpo contra el csf-1r.
EA201171367A1 (ru) Винилиндазолильные соединения
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201590887A1 (ru) Композиция
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM